[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"physiopathology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:physiopathology":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100505271","study-of-neonatal-igg-fc-receptor-expression-in-natural-killer-t-cells-expressing-an-invariant-t-receptor--implication-in-the-pathophysiology-of-systemic-lupus-100505271",false,"NCT05859191","Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus","Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus","FiNKLUPUS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and\u002For secondary Gougerot-Sjögren's\n* Lupus patient, newly diagnosed or known, untreated or in relapse\n* Lupus patient considered stable by the treating practitioner\n* Requiring blood sampling for follow-up\n\nExclusion Criteria:\n\n* Main autoimmune disease other than lupus\n* Patient under legal protection, guardianship or curators\n* Opposition to data processing",true,"ALL","18 Years",{"count":21,"type":22},50,"ESTIMATED","OBSERVATIONAL","This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.",[26,27],"Systemic Lupus Erythematosus","Physiopathology",[29],"lupus","RECRUITING","2026-04-29",{"date":33,"type":34},"2026-04-30","ACTUAL",{"date":36,"type":34},"2023-07-21",{"date":38,"type":22},"2030-07",{"name":40,"class":41},"University Hospital, Tours","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100605739","development-application-and-mechanistic-investigation-of-a-novel-minimally-invasive-bidirectional-epidural-cerebellar-stimulation-technique-for-cerebellar-cognitive-affective-syndrome-100605739","NCT07166432","Development, Application, and Mechanistic Investigation of a Novel Minimally-Invasive Bidirectional Epidural Cerebellar Stimulation Technique for Cerebellar Cognitive Affective Syndrome","Inclusion Criteria:\n\n* 1\\. Clinically and biochemically confirmed ACTH-dependent or ACTH-independent Cushing syndrome (loss of serum cortisol circadian rhythm, elevated 24-hour urinary free cortisol, and failure to suppress on low-dose dexamethasone suppression test).\n\n  2\\. Cranial MRI demonstrating unequivocal cerebellar atrophy (CCAS imaging criterion: cerebellar hemisphere or vermian volume ≥1.5 SD below age-matched normative data).\n\n  3\\. Established clinical diagnosis of CCAS (meets Schmahmann criteria, CCAS-S total score ≥20).\n\n  4\\. Cerebellar ataxia rating scale (SARATA) ≥10, indicating at least moderate motor ataxia.\n\n  5\\. Positive cognitive impairment screen (MoCA \\\u003C26, or Z-scores ≤-1.5 in at least two cognitive domains).\n\n  6\\. Willingness to undergo minimally invasive epidural cerebellar stimulation and provision of written informed consent.\n\nExclusion Criteria:\n\nPatients with significant systemic disease; occurrence of major complications or irreproducible, critical deviations in data collection or experimental procedures; or any circumstance rendering continued participation inappropriate-including clinical deterioration, serious adverse events, or poor compliance-will result in discontinuation of the subject's enrollment.","85 Years",{"count":51,"type":22},200,"Building on previous findings regarding microglial immune function and the immunosuppressive effects of glucocorticoids, this project centers on the cerebellum's role in cognitive science. Using Cushing's syndrome-induced cerebellar atrophy leading to CCAS as a model, we aim to elucidate the pathogenic mechanisms governed by the neuro-adrenal-immune network and to uncover the molecular basis by which a novel minimally invasive brain-machine fusion system ameliorates cerebellar ataxia and cognitive impairment.",[54,55,27],"Cerebellar Atrophy","Etiology","2025-09-03",{"date":58,"type":34},"2025-09-10",{"date":60,"type":34},"2025-06-28",{"date":62,"type":22},"2028-06-01",{"name":64,"class":41},"Peking University First Hospital"]